ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES: EUROPEAN AND AUSTRALIAN PAYER PERCEPTIONS

被引：0
|
作者：
Hogue, S. [1 ]
Brogan, A. P. [1 ]
Croft, E. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] RTI Hlth Solut, Manchester, Lancs, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2027
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY127
引用
收藏
页码：A681 / A681
页数：1
相关论文
共 50 条
  • [31] Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
    Maeda, Kojiro
    Kaneko, Masayuki
    Narukawa, Mamoru
    Arato, Teruyo
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [32] Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
    Kojiro Maeda
    Masayuki Kaneko
    Mamoru Narukawa
    Teruyo Arato
    Orphanet Journal of Rare Diseases, 12
  • [33] Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency
    Mechler, Konstantin
    Mountford, William K.
    Hoffmann, Georg F.
    Ries, Markus
    GENETICS IN MEDICINE, 2015, 17 (12) : 965 - 970
  • [34] ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS
    Dusza, M.
    Kloc, K.
    Remuzat, C.
    Francois, C.
    Toumi, M.
    VALUE IN HEALTH, 2019, 22 : S861 - S861
  • [35] A COMPARATIVE REVIEW OF NICE AND SMC DECISION-MAKING FOR ULTRA-ORPHAN MEDICINES
    Gibbs, K. L.
    Schmetz, A.
    Emich, H.
    Gardner, K.
    VALUE IN HEALTH, 2019, 22 : S861 - S861
  • [36] INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS
    Rousseau, B.
    Poinas, A.
    Oliver, L.
    Collings, H.
    VALUE IN HEALTH, 2017, 20 (09) : A695 - A696
  • [37] Cost effectiveness modelling of enzyme replacement therapy for mucopolysaccharidosis II,an ultra-orphan disease
    Thompson, G.
    Cox, P.
    Clayton, J.
    VALUE IN HEALTH, 2007, 10 (06) : A375 - A375
  • [38] THE NEW SMC ULTRA-ORPHAN PATHWAY: HTA BEST PRACTICE FOR VERY RARE DISEASES?
    Carr, D.
    Macaulay, R.
    VALUE IN HEALTH, 2021, 24 : S241 - S241
  • [39] ORPHAN AND RARE DISEASES - THE PAYER PERSPECTIVE
    Spoors, J.
    Rietveld, A.
    VALUE IN HEALTH, 2014, 17 (07) : A542 - A542
  • [40] Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
    Schlander, Michael
    Adarkwah, Charles Christian
    Gandjour, Afschin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (01) : 171 - 179
12345